[1]
|
K. koga, S. Yamagishi, M. Takeuchi, Y. Inagaki, S. Amano, T. Okamoto, T. Saga, Z. Makita and M. Yoshizuka, “Serum Levels of Glucose-Derived Advanced Glycation End Products Are Associated with the Severity of Diabetic Retinopathy in Type 2 Diabetic Patients without Renal Dysfunction,” International Journal of Clinical Pharmacology Research, Vol. 22, No. 1, 2002, pp. 7-13.
|
[2]
|
L. R. Schwocho and H. N. Masonson, “Pharmacokinetics of CS-866, a New Angiotensin I Receptor Blocker, in Healthy Subjects,” Journal of Clinical Pharmacology, Vol. 41, No. 5, 2001, pp. 515-527.
doi:10.1177/00912700122010393
|
[3]
|
B. S. Lee, M. J. Kang, W. S. Choi, Y. B. Choi, H. S. Kim, S. K. Lee and Y. W. Choi, “Solubilized Formulation of Olmesartan Medoxomil for En-hancing Oral Bioavailability,” Archives of Pharmacal Research, Vol. 32, No. 11, 2009, pp. 1629-1635. doi:10.1007/s12272-009-2117-x
|
[4]
|
O. Sagirli, A. Onal, S. E. Toker and D. ?ensoy, “Simultaneous HPLC Analysis of Olme-sartan and Hydrochlorothiazide in Combined Tablets and in vitro Dissolution Studies,” Chromatographia, Vol. 66, No. 3-4, 2007, pp. 213-218. doi:10.1365/s10337-007-0304-9
|
[5]
|
International Conference on Harmonization (ICH Guide- Lines, Q3A(R) Impurities in New Drug Substances, October 2006.
|
[6]
|
R. B. Gandurib, R. A. Lankaa, et al., “New RP-HPLC Method for The Determination of Olmesartan Medoxomil in Tablet Dosage Form,” Eurasian Journal of Analytical Chemistry, Vol. 5, No. 2, 2010, pp. 145-151.
|
[7]
|
A. R. Rote and P. D. Bari, “Spectrophotometric Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in Tablet,” Indian Journal of Pharmaceutical Sciences, Vol. 72, No. 1, 2010, pp. 111-113.
doi:10.4103/0250-474X.62245
|
[8]
|
Stability Testing of New Drug Substances and Drug Products Q1 A (R2), International Conference on Harmonization, IFPMA, Geneva, 2003.
|
[9]
|
USP 2011 United States of Pharmacopoeia, 34th Edition, “United States Pharmacopial Drug Stability Principles and Practices (2000),” In: J. T. Carstensen and C. T. Rhodes, Eds., 3rd Edition, Marcel Dekker, New York.
|
[10]
|
M. Bakshi and S. Singh, “Development of Validated Stability Indicating Assay Methods Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040.
doi:10.1016/S0731-7085(02)00047-X
|
[11]
|
R. N. Sharma and S. S. Pnacholi, “RP-HPLC-DAD Method for Determination of Olmesartan Medoxomil in Bulk Drug and Tablets Exposed to Forced Conditions,” Acta Pharmaceutica, Vol. 61, No. 1, 2010, pp. 13-24.
doi:10.2478/v10007-010-0010-2
|
[12]
|
P. Sengupta, A. Das and T. K. Pal, “Stability Indicating RP-HPLC Method for Simulta-neous Determination of Olmesartan Medoxamil and Pioglitazone in Fixed Dose Combination Tablet Dosage Form,” Vol. 22, No. 8, 2010, pp. 6471-6479.
|